The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access	neoplasm	Recruiting	Not stated	2026-06-24		NCT02834884
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Active, not recruiting	Phase 2	2024-11-05		NCT04127110

Clinical trials